Sangamo Therapeutics Executive Compensation Details
Ticker: SGMO · Form: DEF 14A · Filed: Apr 30, 2025 · CIK: 1001233
| Field | Detail |
|---|---|
| Company | Sangamo Therapeutics, Inc (SGMO) |
| Form Type | DEF 14A |
| Filed Date | Apr 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
Related Tickers: SGMO
TL;DR
Sangamo's 2024 exec comp details are out - equity awards are the focus.
AI Summary
Sangamo Therapeutics, Inc. filed its DEF 14A on April 30, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted, outstanding awards, and changes in their fair value for both principal executive officers (PEO) and non-PEO/NEO individuals. Specific dollar amounts for these awards are detailed within the compensation tables.
Why It Matters
This filing provides transparency into how Sangamo Therapeutics compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: low — This is a routine proxy statement detailing executive compensation and does not present new material risks.
Key Numbers
- 2024 — Fiscal Year End (Executive compensation data pertains to this year.)
- 20250430 — Filing Date (Date the DEF 14A was filed with the SEC.)
- 20250612 — Period of Report (The period covered by the proxy statement.)
Key Players & Entities
- SANGAMO THERAPEUTICS, INC (company) — Filer
- 501 CANAL BLVD. (address) — Business and Mail Address
- RICHMOND (location) — City
- CA (location) — State
- 94084 (postal_code) — ZIP Code
- SANGAMO BIOSCIENCES INC (company) — Former Company Name
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is filed by a company to solicit proxies from its shareholders for an upcoming annual or special meeting. It contains detailed information about matters to be voted on, including executive compensation, director nominations, and other corporate governance issues.
What specific fiscal year does the compensation information in this filing primarily cover?
The compensation information in this filing primarily covers the fiscal year ending December 31, 2024.
What types of equity awards are detailed in the compensation tables?
The filing details equity awards granted, outstanding and unvested awards at year-end, and changes in the fair value of these awards.
Who are the two main categories of individuals for whom compensation data is presented?
The compensation data is presented for Principal Executive Officers (PEO) and Non-PEO/NEO (Non-Principal Executive Officer/Named Executive Officer) individuals.
When was Sangamo Therapeutics, Inc. formerly known as Sangamo BioSciences Inc.?
Sangamo Therapeutics, Inc. was formerly known as Sangamo BioSciences Inc. prior to a name change on February 8, 2000.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 30, 2025 regarding SANGAMO THERAPEUTICS, INC (SGMO).